Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Editorial

Challenges in understanding Sjögren's syndrome - improved insights into the pathogenesis generate hope for innovative therapies?

Thomas Dörner

Author Affiliations

CC12, Charite Universitätsmedizin Berlin, Chariteplatz 01, 10098 Berlin, Germany

Arthritis Research & Therapy 2011, 13:123  doi:10.1186/ar3425


See related reviews by Jacob and Stohl, http://arthritis-research.com/content/13/4/228; Shao and Cohen, http://arthritis-research.com/content/13/1/202; Holle et al., http://arthritis-research.com/content/13/3/224; Sipsas et al., http://arthritis-research.com/content/13/2/212; Vitali, http://arthritis-research.com/content/13/4/233; Low and Witte, http://arthritis-research.com/content/13/3/218; Youinou and Pers, http://arthritis-research.com/content/13/4/227; Delaleu et al., http://arthritis-research.com/content/13/3/217; and Kallenberg et al., http://arthritis-research.com/content/13/1/205

Published: 19 August 2011

Abstract

The reviews in this series on Sjögren syndrome provide an up-to-date summary and perspectives on the pathogenesis of this interesting entity with glandular and frequently systemic manifestations, the value of preclinical models, and our current understanding of therapeutic approaches. The last of these includes what has been learned from trials blocking tumor necrosis factor and, more recently, anti-CD20 therapy. Potential therapeutic targets, such as blockade of the B cell-activating factor, the role of interferon-alpha, and targeting CD22, are discussed.